Published in Ned Tijdschr Geneeskd on December 04, 2004
Sentinel node biopsy for breast cancer patients: issues for discussion and our practice. Patholog Res Int (2010) 0.75
[Detailed pathological examination of the sentinel lymph nodes in order to detect micrometastases: no clinical relevance in patients with breast cancer]. Ned Tijdschr Geneeskd (2005) 0.75
[Sentinel node biopsy in breast cancer: pathological analysis and interpretation]. Pathologe (2009) 0.75
Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med (1988) 4.06
Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg (1999) 3.56
Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet (1998) 3.06
Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol (1994) 2.92
Feasibility and effects of decision aids. Med Decis Making (2000) 2.83
Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol (2008) 2.73
Ductal carcinoma in-situ of the breast; second EORTC consensus meeting. Eur J Cancer (1992) 2.67
[The treatment of ductal carcinoma in situ (DCIS) of the breast]. Ned Tijdschr Geneeskd (2003) 2.67
Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol (2001) 2.51
Reduction in the number of sentinel lymph node procedures by preoperative ultrasonography of the axilla in breast cancer. Eur J Cancer (2003) 2.40
[Dutch Institute for Healthcare Improvement guideline, "Treatment of breast cancer"]. Ned Tijdschr Geneeskd (2002) 2.39
Patients with penile carcinoma benefit from immediate resection of clinically occult lymph node metastases. J Urol (2005) 2.31
How to avoid false-negative dynamic sentinel node procedures in penile carcinoma. J Urol (2004) 2.29
Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol (2001) 2.28
Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol (1997) 2.15
The contribution of routine follow-up mammography to an early detection of asynchronous contralateral breast cancer. Cancer (1991) 2.10
[Guideline 'Melanoma' (3rd revision)]. Ned Tijdschr Geneeskd (2005) 2.08
E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer (1997) 2.02
Angiosarcoma of the breast after conservation therapy for invasive cancer, the incidence and outcome. An unforseen sequela. Breast Cancer Res Treat (1998) 1.97
The impact of tumor size and histology on local control after breast-conserving therapy. Radiother Oncol (1988) 1.83
Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. Ann Oncol (2002) 1.80
Anatomy and physiology of lymphatic drainage of the breast from the perspective of sentinel node biopsy. J Am Coll Surg (2001) 1.79
Reliability of sentinel lymph node biopsy for staging melanoma. Br J Surg (2000) 1.71
Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: A systematic review and meta-analysis of the literature. Eur J Surg Oncol (2008) 1.69
Positive iliac and obturator nodes in melanoma: survival and prognostic factors. Ann Surg Oncol (1999) 1.55
Histological determinants for different types of local recurrence after breast-conserving therapy of invasive breast cancer. Dutch Study Group on local Recurrence after Breast Conservation (BORST) Eur J Cancer (1999) 1.55
Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs. J Am Coll Surg (1996) 1.54
Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res (1992) 1.53
Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients. J Surg Oncol (2005) 1.52
Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer (2003) 1.50
Causes of inconsistency in diagnosing and classifying intraductal proliferations of the breast. European Commission Working Group on Breast Screening Pathology. Eur J Cancer (2000) 1.50
High incidence of in-transit metastases after sentinel node biopsy in patients with melanoma. Br J Surg (2004) 1.46
Clear cell sarcoma (malignant melanoma) of soft parts: A clinicopathologic study of 30 cases. Cancer (1999) 1.46
Safety and efficacy of isolated limb perfusion in elderly melanoma patients. Ann Surg Oncol (2002) 1.46
Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat (2008) 1.45
Variations in diagnostic and therapeutic procedures in a multicentre, randomized clinical trial (EORTC 10853) investigating breast-conserving treatment for DCIS. Eur J Surg Oncol (2001) 1.44
Excision biopsy of breast lesions changes the pattern of lymphatic drainage. Br J Surg (2007) 1.43
[Diagnostics in clinically occult, radiologically suspect breast lesions more often surgery than needle diagnostics with image monitoring]. Ned Tijdschr Geneeskd (2001) 1.43
ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. Am J Hum Genet (2000) 1.42
[Identification of the sentinel node in patients with breast carcinoma]. Ned Tijdschr Geneeskd (1996) 1.42
Finding lymph node metastases in invasive breast cancer: sampling or sentinel node procedure? Eur J Surg Oncol (2002) 1.39
[Tumor markers in screening, diagnosis and treatment of patients with breast carcinoma]. Ned Tijdschr Geneeskd (1993) 1.38
Decision support for patients with early-stage breast cancer: effects of an interactive breast cancer CDROM on treatment decision, satisfaction, and quality of life. J Clin Oncol (2001) 1.36
[Less mutilating treatment of penile carcinoma]. Ned Tijdschr Geneeskd (2005) 1.35
Lymphoepithelioma-like carcinoma of the breast: lack of evidence of Epstein-Barr virus infection. Histopathology (2001) 1.32
Pathological work-up of sentinel lymph nodes in breast cancer. Review of current data to be considered for the formulation of guidelines. Eur J Cancer (2003) 1.31
Nipple-sparing mastectomy in breast cancer: a viable option? Eur J Surg Oncol (2001) 1.29
Expression of oestrogen receptor and loss of E-cadherin are diagnostic for gastric metastasis of breast carcinoma. Histopathology (2005) 1.27
Evaluation of mammary lymphoscintigraphy by a single intratumoral injection for sentinel node identification. J Nucl Med (2000) 1.25
Resectable retroperitoneal soft tissue sarcomas. The effect of extent of resection and postoperative radiation therapy on local tumor control. Cancer (1994) 1.25
Consistency achieved by 23 European pathologists from 12 countries in diagnosing breast disease and reporting prognostic features of carcinomas. European Commission Working Group on Breast Screening Pathology. Virchows Arch (1999) 1.24
Acinic cell carcinoma of the breast: an immunohistochemical and ultrastructural study. Virchows Arch (2000) 1.24
Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ. Br J Cancer (2001) 1.22
The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma. Histopathology (2007) 1.21
Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations. Cancer Res (1994) 1.21
No common denominator for breast cancer lymph node metastasis. Br J Cancer (2005) 1.20
Discrepancies in current practice of pathological evaluation of sentinel lymph nodes in breast cancer. Results of a questionnaire based survey by the European Working Group for Breast Screening Pathology. J Clin Pathol (2004) 1.19
Consistency of staining and reporting of oestrogen receptor immunocytochemistry within the European Union--an inter-laboratory study. Virchows Arch (2004) 1.19
Frozen section investigation of the sentinel node in malignant melanoma and breast cancer. Ann Surg Oncol (2001) 1.19
Diagnostic accuracy for different strategies of image-guided breast intervention in cases of nonpalpable breast lesions. Br J Cancer (2004) 1.18
Detection of unknown occult primary tumors using positron emission tomography. Cancer (1998) 1.18
Immunohistochemical categorisation of ductal carcinoma in situ of the breast. Br J Cancer (2007) 1.17
Genetic alterations on chromosome 16 and 17 are important features of ductal carcinoma in situ of the breast and are associated with histologic type. Br J Cancer (1999) 1.17
Breast-conserving therapy for Paget disease of the nipple: a prospective European Organization for Research and Treatment of Cancer study of 61 patients. Cancer (2001) 1.16
Morbidity of dynamic sentinel node biopsy in penile carcinoma. J Urol (2005) 1.15
Clinical relevance of sentinel lymph nodes outside the axilla in patients with breast cancer. Br J Surg (2000) 1.13
Localizing the sentinel node in cutaneous melanoma: gamma probe detection versus blue dye. Ann Surg Oncol (1997) 1.13
In-situ breast cancer: the EORTC consensus meeting. Lancet (1989) 1.13
Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple mRNA markers. Br J Cancer (2004) 1.11
Long-term prognosis of patients with local recurrence after conservative surgery and radiotherapy for early breast cancer. Eur J Cancer (2005) 1.10
The hidden sentinel node in breast cancer. Eur J Nucl Med Mol Imaging (2002) 1.10
Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancer. J Pathol (2009) 1.09
Toker cells are probably precursors of Paget cell carcinoma: a morphological and ultrastructural description. Virchows Arch (2002) 1.09
Cyclin D1 gene amplification and overexpression are present in ductal carcinoma in situ of the breast. J Pathol (1999) 1.08
Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. Ann Oncol (2006) 1.08
Alveolar soft part sarcoma. a report of 15 cases. Eur J Cancer (2002) 1.08
Primary axillary radiotherapy as axillary treatment in breast-conserving therapy for patients with breast carcinoma and clinically negative axillary lymph nodes. Cancer (2000) 1.07
European guidelines for quality assurance in the surgical management of mammographically detected lesions. European Breast Cancer Working Group. Ann Chir Gynaecol (1998) 1.07
Genetic counseling for hereditary cancer: a pilot study on experiences of patients and family members. Patient Educ Couns (1997) 1.05
Immunohistochemical detection of the neu protein in tissue sections of human breast tumors with amplified neu DNA. Oncogene (1988) 1.05
History of sentinel node and validation of the technique. Breast Cancer Res (2001) 1.05
Single intralesional tracer dose for radio-guided excision of clinically occult breast cancer and sentinel node. Ann Surg Oncol (2001) 1.04
Malignant neoplasms infiltrating pseudoangiomatous' stromal hyperplasia of the breast: an unrecognized pathway of tumour spread. Histopathology (2002) 1.04